ARGONAUT: Stool and Blood Sample Bank for Cancer Patients

Launched by PERSEPHONE BIOSCIENCES · Nov 16, 2020

Keywords

ClinConnect Summary

The ARGONAUT study is a research project aimed at understanding how certain bacteria in our gut (the microbiome) can influence cancer treatment and outcomes for patients with advanced-stage cancers. The study is looking at patients with four types of cancer: non-small cell lung cancer, colorectal cancer, triple-negative breast cancer, and pancreatic cancer. Up to 5,000 participants will be enrolled, including healthy individuals with no cancer diagnosis but who may be at higher risk for colorectal cancer. By collecting stool and blood samples over two years, researchers hope to find important markers that can help doctors choose the best treatment options for their patients.

To be eligible for the study, participants need to be at least 18 years old and have stage III or IV cancer, or be a healthy person undergoing a routine colonoscopy. Participants will provide samples and answer questions about their health, and their medical records may be reviewed over time. This study is currently recruiting participants, and it aims to gather valuable information that can lead to better cancer therapies tailored to individual needs.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Men or women who are ≥ 18 years old with stage III or stage IV non-small cell lung cancer (NSCLC), colorectal cancer, triple-negative breast cancer, or pancreatic cancer treated by a particular cancer treatment for the first time, OR healthy subjects undergoing a standard of care colonoscopy
• • Subjects able to provide written informed consent
• Exclusion Criteria:
• • Subjects with known HIV, Hepatitis A, Hepatitis B, Hepatitis C, or SARS-CoV2
• • Subjects without the mental capacity to complete either a written or online questionnaire, alone or with assistance, or make sound decisions
• • Women who are pregnant or who plan on becoming pregnant
• • Women who are nursing